BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rcadia Awarded Four U.S. Patents Covering Technology for Automated Analysis of Coronary CT Angiography


6/28/2011 8:34:07 AM

NEWTON, Mass., June 28, 2011 /PRNewswire/ -- Rcadia Medical Imaging today announced that the company has been granted four patents by the U.S. Patent and Trademark Office covering technology for its COR Analyzer® System. The COR Analyzer performs fully automatic analysis of Coronary CT Angiography (cCTA) studies to accelerate emergency department triage of suspected coronary artery disease (CAD) patients and optimize cardiology and radiology department workflow. The System is marketed in the U.S. and distributed through an agreement with Siemens Healthcare.

"The COR Analyzer is a powerful decision support tool which has shown great potential in clinical trials and routine use to reduce unnecessary admissions and shorten time to treatment," said Shai Levanon, President and CEO of Rcadia. "The patents strengthen the intellectual property position around this innovative system." He noted that the COR Analyzer is the first of a new category of software applications to broadly enable the use of advanced imaging technologies in emergency medicine to improve care and reduce costs.

The four patents broadly cover methods and algorithms for automated analysis of coronary CT angiography studies and detection of pathologies in coronary arteries. The patents also cover methods for results visualization and automatic assessment of study quality. In addition, the methods are extended to cover the automatic interpretation of triple rule out studies.

Triage of suspected CAD patients represents a major clinical and healthcare economic challenge in the U.S. An estimated six million patients enter the ED in the U.S. each year with chest pain. Because current diagnostic techniques are often equivocal, an estimated two million, primarily low risk patients, are admitted to the hospital for further testing at an annual cost of $10-$13 billion. In an estimated 85 percent of these patients, an acute coronary event is subsequently ruled out.

About Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT Angiography to enable the practical application of cCTA in detecting significant coronary artery disease. The COR Analyzer improves the utility of Coronary CTA studies in the emergency department to triage chest pain patients and optimizes work flow in cardiology and radiology departments. Learn more at www.rcadia.com.

SOURCE Rcadia Medical Imaging Ltd.



Read at BioSpace.com

Rcadia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES